Early clinical trials established the safety and feasibility of closed-loop insulin delivery, but the 2019 iDCL trial1 marked the first large, outpatient, randomised, controlled trial to show a ...

Plovanic noted that fourth-quarter results and 2026 outlook met expectations, as the company’s strategy remains unchanged. Management continues to focus on product refinements across the U.S.

The company has integrated its Eversense 365 implant with Sequel Med Tech’s insulin delivery system to automate the management of Type 1 diabetes.

Senseonics SENS recently announced the full availability of its long-term, implantable Continuous Glucose Monitoring (CGM) ...

Urinary tract infections (UTIs) are among the most common bacterial infections, with catheter-associated UTIs accounting for ...

Sequel Med Tech and (NYSE:SENS) today announced the full U.S. launch of their CGM and insulin pump integration.

The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes ...

Dexcom is already working on its G8 sensor for continuous glucose monitoring (CGM). But before you get too excited, the product is still a couple of years out, CEO Jake Leach told MD+DI during the J.P ...

DexCom, incorporated in Delaware and headquartered in San Diego, California, designs, manufactures, and markets continuous glucose monitoring (CGM) systems to help individuals with types 1 and 2 ...

When Dan Heller received his first batch of Dexcom’s latest continuous glucose monitors in early 2023, he decided to run a small experiment: He wore the new biosensor and the previous generation at ...

NEW YORK CITY, NY / ACCESS Newswire / December 1, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against DexCom, Inc. ("DexCom" or the "Company") (NASDAQ:DXCM) and certain ...